Elevation Oncology to Participate at Upcoming Investor Conferences
Elevation Oncology (Nasdaq: ELEV) announced participation in key investor conferences this March. They will attend the Cowen 43rd Annual Health Care Conference on March 7 at 12:50 p.m. ET focusing on GI/GU Oncology. Additionally, they will present at the Oppenheimer 33rd Annual Healthcare Conference on March 15 at 8:00 a.m. ET. A live webcast and replay will be accessible on their Investor Relations website. Elevation Oncology is dedicated to developing selective cancer therapies, like their lead candidate, EO-3021, targeting Claudin18.2.
- None.
- None.
NEW YORK, March 1, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that management will participate in the following investor conferences in March:
Cowen 43rd Annual Health Care Conference
Date: Tuesday, March 7
Panel Title: GI/GU Oncology
Panel Time: 12:50 p.m. ET
Oppenheimer 33rd Annual Healthcare Conference
Date: Wednesday, March 15
Presentation Time: 8:00 a.m. ET
A live webcast and replay of the event will be available on the Events page of the Company's Investor Relations website at https://investors.elevationoncology.com.
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are rethinking drug development by seeking out innovative, selective cancer therapies that can be matched to a patient's unique tumor characteristics. Our lead candidate, EO-3021, is a potential best-in-class, antibody drug conjugate (ADC) designed to target Claudin18.2, a clinically validated molecular target that can selectively deliver a cytotoxic payload directly to kill cancer cells. We are working to rapidly advance EO-3021 into the clinic in the US across a range of solid tumor indications to demonstrate its potential, as well as exploring other opportunities through new or existing partnerships and business development opportunities to expand our novel oncology pipeline. For more information, visit www.ElevationOncology.com.
Elevation Oncology Investor and Media Contact
Candice Masse, 978-879-7273
Senior Director, Corporate Communications & Investor Relations
cmasse@elevationoncology.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-participate-at-upcoming-investor-conferences-301758509.html
SOURCE Elevation Oncology
FAQ
What conferences will Elevation Oncology attend in March 2023?
What is the focus of Elevation Oncology's presentations at these conferences?
What time will Elevation Oncology present at the Cowen Conference?
When is Elevation Oncology's presentation at the Oppenheimer Conference?
How can I access the webcast of the Elevation Oncology presentations?
